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SUMMARY
This protocol describes a synthetic genomics pipeline to clone and engineer the
entire 190-kbp genome of the African swine fever virus (ASFV) genotype II in
yeast using transformation-associated recombination cloning. The viral genome
was cloned using DNA directly extracted from a clinical sample. In addition, the
precise deletion of a non-essential gene and its replacement by a synthetic
reporter gene cassette are presented. This protocol is applicable to other
ASFV genotypes and other large DNA viruses.
BEFORE YOU BEGIN
ASFV causes a devastating hemorrhagic disease in pigs with a mortality often reaching up to 100%
(Sánchez-Cordón et al., 2018). ASFV is rapidly spreading throughout Europe and Asia, already
responsible for the loss of approximatively a third of the world’s pig population. The development
of effective treatments and vaccines are hindered due to knowledge gaps regarding the biology of
the virus (Sánchez et al., 2019).
ASFV is a large DNA virus belonging to the Asfarviridae family with a genome size ranging between
170 and 190 kbp (Dixon et al., 2013), a size problematic to be stably maintained in E. coli-based sys-
tems commonly used to generate and mutagenize molecular clones. The generation of defined
ASFV mutants still relies on homologous recombination methods mainly involving eukaryotic cells
such as swine macrophages (Borca et al., 2021; Gallardo et al., 2018; Monteagudo et al., 2017;
O’Donnell et al., 2015), although the use of CRISPR-Cas9 technology was recently implemented
(Borca et al., 2018). In addition, ASFV replication in cell culture has been reported to result in adap-
tive single nucleotide mutations, genome deletions and rearrangements associated with phenotype
changes (Borca et al., 2021; Krug et al., 2015).
Here we describe a yeast-based protocol for the cloning and engineering of an ASFV isolate
belonging to the genotype II, the genotype responsible for the current pandemic in Europe and
Asia. This pipeline relies on the transformation-associated recombination (TAR) cloning strategy,
which was originally developed for the selective isolation and maintenance of large eukaryotic
DNA regions in Saccharomyces cerevisiae (Larionov et al., 1996). The TAR cloning method uses
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the superior capacities of the yeast to perform in vivo homologous recombination and diverts it in
order to recombine several overlapping DNA fragments together. This system was adopted to
reconstruct the genome of the first synthetic mycoplasma cell (Syn 1.0; Gibson et al., 2010), but
was also applied to other large DNA viruses such as the Herpes simplex virus type 1 (HSV-1; Oldfield
et al. 2017) and, more recently, to RNA viruses including the SARS-CoV-2 (Thao et al., 2020).
This protocol includes all the necessary steps from the extraction of ASFV genomic DNA from clinical
samples up to the reconstruction of full-length ASFV genomes, natural or engineered, in the yeast
S. cerevisiae. This protocol does not include a rescue system, which has to be developed and
adapted separately for the different viruses to be tackled.
Biosafety
In Switzerland, ASFV is a risk group 4 pathogen and hence all work involving live virus was carried out
in the BSL-3Ag containment facility of the Institute of Virology and Immunology in Mittelhäusern
(Switzerland). After inactivation, the sera from ASFV-infected pigs were transferred out of the
BSL-3Ag environment to standard BSL-2 laboratories, where the extraction of the viral genomic
DNA and all the following steps of this protocol were performed. Animal experiments were conduct-
ed at the IVI in compliance with the animal welfare regulation of Switzerland under the cantonal
license BE18/2019.
Design of the ASFV genome reconstruction
Timing: 2 h (user dependent)
The in silico design used in this protocol involves the fragmentation of the ASFV genome into seven
sub-genomic fragments as presented in Figure 1.
1. The 50 and 30-ends of the ASFV genome, consisting of inverted-terminal-repeats (ITRs), are
chemically-synthetized (GenScript) in order to prevent any illegitimate recombination events
during the final reassembly in yeast.
Figure 1. TAR cloning design for the reconstruction of the ASFV genome
The genome was divided into seven sub-genomic fragments. Fragments 1 and 2, encompassing highly repetitive
ITRs, were chemically-synthetized. Both contain an artificial 50-bp sequence stretch (in pink) at their 50 and 30-ends,
respectively. These 50-bp stretches will be clipped off via restriction endonucleases indicated by the asterisks after
full-length genome assembly. Positions indicated for each of the seven sub-genomic fragments correspond to the
ASFV nucleotide sequence as provided in GenBank.
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a. Both synthetic fragments, named Fragment 1 and 2 respectively, are ligated into the vector
pUC57 using the unique EcoRV restriction site, clone in E. coli and sequence-verified.
b. They contain two SmaI restriction sites at their 50 and 3‘-ends, allowing their excision from the
pUC57 vector.
c. Fragment 1 is a 2,090-bp dsDNA fragment consisting of a 50-bp unique region (randomly
designed for site-directed TAR cloning purposes), followed by an I-SceI restriction site and
by the first 2,010 nucleotides of the ASFV genome.
d. Fragment 2 consists of the last 1,736 nucleotides of the ASFV genome followed by an I-SceI
restriction site and by another 50-bp unique region (also randomly designed for TAR cloning).
e. Their corresponding sequences are provided as supplementary material.
2. The other five sub-genomic fragments ranging in size from 12.4 to 49.6 kbp were isolated using
the TAR cloning method. Their corresponding start and end positions are displayed in Figure 1.
a. Fragment 4, 5 and 6 mainly contain genes encoding proteins involved in virus replication and
structure.
b. Fragments 3 and 7 encompass genes included in multi-gene family (MGF) 100, 110, 360 and
505, most of which still have an unknown function (Dixon et al., 2013; Zhu et al., 2020).
c. Alternative designs consisting of different numbers of sub-genomic fragments with different 5’
and/or 30-ends are generally possible, but have not been investigated here. As a general rule
of thumb, fragmentation designs aiming for a higher number of shorter sub-genomic frag-
ments require more experimental time (both in term of design and isolation of these genomic
intermediates) but will ultimately result in more flexible assemblies.
Design of the primers
Timing: 1 h–2 h (user dependent)
Primers used throughout the protocol are listed in the key resources table (here).
3. In addition to their 30-binding regionswith the pCC1BAC-Ura3(-His3) TAR vectors, all the primers used
for TAR cloning contain a 50-bp region (in bold) complementary to the 50-end (reverse primers) or the
30-end (forward primers) of the ASFV sub-genomic fragment of interest. Such overlaps (also called
hooks) are required for the specific and legitimate homologous recombination in yeast.
4. The presence of an I-SceI restriction site (underlined) allows the linearization of the ASFV sub-
genomic fragments after their isolation and purification as yeast artificial chromosomes (YACs).
5. Due to their length, all primers used for TAR cloning are purified on polyacrylamide gel
electrophoresis (PAGE purified) (Microsynth, Balgach, Switzerland). All other primers used for
the PCR-based screening and multiplex PCRs of the different yeast clones were only desalted
after synthesis.
REAGENT or RESOURCE SOURCE IDENTIFIER
Bacterial and virus strains
Stellar competent E. coli Takara Bio 636763
TransforMax Epi300 Electrocompetent E. coli Epicentre/Lucigen EC300110
ASFV isolate Georgia 2007 LMA, Tbilisi (Georgia) This work
Experimental models: Organisms/strains
S. cerevisiae VL6-48N JCVI Noskov et al., 2002
Recombinant DNA
pCC1BAC-His3/Ura3 JCVI Gibson et al., 2010
pUC57-P_Pol-secNluc _C962R-int GenScript This work
pUC57-P_Pol-eGFP_C962R-int GenScript This work
pUC57-Fragment1 GenScript This work
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
pUC57-Fragment2 GenScript This work
Oligonucleotides


























































Screening of yeast transformants (internal fragments)
ASFVint-3F: ccttagtagcggcagatacc
This paper N/A
ASFVint-3R: atggacaggtttcaatgctcg This paper N/A
ASFVint-4F: tcgcatttcgtgttgaaatacg This paper N/A
ASFVint-4R: gcattcctgcctattaatgtgc This paper N/A
ASFVint-5F: gttcaagtggtggaggctc This paper N/A
ASFVint-5R: agccttccaacgtgttgttgc This paper N/A
ASFVint-6F: gagtgcacgtatcagattacg This paper N/A
ASFVint-6R: tcgtggtgttcaaggtaatcg This paper N/A
ASFVint-7F: gcattaatgaaagctgtacagg This paper N/A
ASFVint-7R: gttgaagtccatgaatctctgg This paper N/A
Screening of yeast transformants (junctions) pCC1jct-F1:
ccattcagctgcgcaactg
This paper N/A
ASFVFg3-R: tataagcttactgaagccatcc This paper N/A
ASFVFg3-F: ctgattaaagcgacaatcttacg This paper N/A
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
pCC1jct-R1: cttccatgtcggcagaatgc This paper N/A
ASFVFg4-R: ctaccaaaacctctctacatgc This paper N/A
ASFVFg4-F: ccaactccttagggaatatcc This paper N/A
ASFVFg5-R: cgatatggacgatgtccagc This paper N/A
ASFVFg5-F: tttcggcatatccagcctcc This paper N/A
ASFVFg6-R: ctccgagctgcacttttacg This paper N/A
ASFVFg6-F: agtattattagaaatggctgtcg This paper N/A
ASFVFg7-R: agagattctcctgttattgtgg This paper N/A
ASFVFg7-F: tgacctgtagtacgtatgatgg This paper N/A
Screening of final ASFV constructs (multiplex PCR for junctions)
Multiplex PCR 1 pCC1jct-F1: ccattcagctgcgcaactg
This paper N/A
ASFVFg1-R: tgaatcggattcatggcatgc This paper N/A
ASFVFg3-F2: gttggcaacaatccacagacg This paper N/A
ASFVFg4-R2: cagtctttacaggaaacatgg This paper N/A
ASFVFg4-F: ccaactccttagggaatatcc This paper N/A
ASFVFg5-R: cgatatggacgatgtccagc This paper N/A
ASFVFg2-F: tgacattgcgatccgtacaattgc This paper N/A




ASFVFg3-R: tataagcttactgaagccatcc This paper N/A
ASFVFg5-F: tttcggcatatccagcctcc This paper N/A
ASFVFg6-R: ctccgagctgcacttttacg This paper N/A
ASFVFg6-F: agtattattagaaatggctgtcg This paper N/A
ASFVFg7-R: agagattctcctgttattgtgg This paper N/A
ASFVFg7-F: tgacctgtagtacgtatgatgg This paper N/A
ASFVFg2-R: acgtatagttgataaaagtgctgg This paper N/A
Screening for eGFP and secNluc reporters integration
ASFVreporter-F: gattataaagagtaactcgtagagg
This paper N/A
ASFVreporter-R: acatgttacgtacagttcacttcc This paper N/A
Chemicals, peptides, and recombinant proteins
YPDA Takara Bio 630306
SD broth (with 2% glucose) Formedium CSM0205
-His single Drop-out Formedium DCS0071
-Ura single Drop-out Formedium DCS0161
Minimal SD Agar Base Takara Bio 630412
Difco LB Agar, Lennox DB 240110
Dulbecco’s Phosphate Buffered Saline (103), no calcium, no
magnesium
Thermo Fischer 14200067
Lithium acetate dihydrate Sigma-Aldrich L4158
ssDNA sodium salt Sigma-Aldrich D1626
PEG3350 Sigma-Aldrich P4338-500G
Chelex 100 sodium form Sigma-Aldrich 95577-100G-F
Glass beads, acid washed Sigma-Aldrich G8772-100G
PrimeSTAR GXL DNA polymerase Takara Bio R050B
GoTaq G2 Green Master Mix Promega M7823
Multiplex PCR Kit QIAGEN 206143
Zymolyase-100T AMSBIO 120493-1
Glycoblue Coprecipitant (15 mg/mL) Thermo Fischer AM9516
Ribonucleic acid, transfer from baker’s yeast Sigma R5636-1ML
Sodium acetate 3M, pH5.2 Thermo Fischer R1181




(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
CopyControl Induction solution Lucigen CCIS125
Critical commercial assays
MagAttract HMW DNA Kit QIAGEN 67563
QIAprep Spin Miniprep Kit QIAGEN 27106
QIAGEN Plasmid Midi Kit QIAGEN 12143
QIAGEN Large-Construct Kit QIAGEN 12462
High Pure PCR Product Purification Kit Merck 11732668001
QIAquick Gel Extraction Kit QIAGEN 28704
Other
Optima L-90K Ultracentrifuge with SW41Ti swinging-bucket rotor Beckman Coulter N/A
Biospectrophotometer Eppendorf 6135000009
Lab Armor Bead Bath LabArmor M706
Thermomixer C Eppendorf 5382000015
UltraSlim LED Transilluminator MaestroGen SLB-01W
Ultra-Clear Centrifuge Tubes (14 3 89 mm, 13.2 mL) Beckman Coulter 344059
Gene Pulser Xcell Electroporation System Bio-Rad 165–2660/68
Roti-Store yeast cryo vials Carl Roth X983.1
Roti-Store yeast cryo vials (for E. coli) Carl Roth P730.1
Gene Pulser/MicroPulser Electroporation Cuvettes, 0.1 cm gap Bio-Rad 1652089
X-tracta Gel Extractor Tool Sigma-Aldrich Z722390




Reagents Final concentration Amount
Zymolyase-100T 10 mg/mL 200 mg
Glycerol (50% v/v) 25% (v/v) 10 mL
Tris-HCl (1M, pH7.5) 50 mM 1 mL
ddH2O n/a 9 mL
Total n/a 20 mL
Solution can be stored in 0.5 mL-aliquots at 20C up to 1 year. Avoid excessive freezing/thawing cycles.
SPEM solution
Reagents Final concentration Amount
Na2HPO4.2H2O 7.75 mM 0.69 g
NaH2PO4.2H2O 2.31 mM 0.18 g
EDTA (0,5M, pH7,5) 10 mM 10 mL
Sorbitol 1 M 91 g
ddH2O n/a Up to 500 mL
Sterilized on 0.22 mm filter
Total n/a 500 mL
Store at 20C–25C up to 1 year.
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STC solution
Reagents Final concentration Amount
Sorbitol 1 M 18.2 g
Tris (1M, pH7.5) 10 mM 1 mL
CaCl2 (1M) 10 mM 1 mL
ddH2O n/a Up to 100 mL
Sterilized on 0.22 mm filter
Total n/a 100 mL
Store at 20C–25C for up to 3 months.
SOS solution
Reagents Final concentration Amount
Sorbitol 1 M 9.1 g
Yeast extract n/a 0.125 g
Bacto peptone n/a 0.25 g
CaCl2 (1M) 0.6 mM 300 mL
ddH2O n/a Up to 50 mL
Sterilized on 0.22 mm filter
Total n/a 50 mL
Store at 20C–25C up to 1 year.
Sorbitol plates
Reagents Final concentration Amount
Sorbitol 1 M 91 g
SD Base Agar n/a 23.35 g
-His (or –Ura) n/a 0.35 g
ddH2O n/a Up to 500 mL
Adjust the pH to 5.8 and autoclave 121C 15min
Total 25 mL/plate 500 mL
Store upside down at 4C up to 2/3 weeks.
PEG solution
Reagents Final concentration Amount
PEG 8000 n/a 10 g
Tris-HCl (1M, pH7.5) 10 mM 500 mL
CaCl2 1M 10 mM 500 mL
ddH2O n/a Up to 50 mL
Adjust the pH to 7.5 and sterilized on 0.22 mm filter
Total n/a 50 mL
Prepare fresh for every transformation and place at 20C–25C during the experiment.
TOP agar
Reagents Final concentration Amount
Sorbitol 1 M 45.5 g
SD base n/a 6.72 g
-His (or -Ura) n/a 0.2 g
Bacto agar n/a 7.5 g
ddH2O n/a Up to 250 mL
Adjust the pH to 5.8 and autoclave 121C 15min
Total 12.5 mL /plate 250 mL
Prepare fresh on the morning of each transformation and place at 55C in a water/bead bath until needed.
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Concentration of ASFV particles and isolation of high molecular weight viral genomic DNA
Timing: 2 h
This step describes the concentration of viral particles from the serum of domestic pigs experi-
mentally infected experimentally with ASFV via ultracentrifugation and the subsequent isolation
of high molecular weight viral DNA (vDNA). Organ material from a field case of ASF in Western
Georgia in June 2007 was obtained from Tinatin Onashvili and Cezar Machitidze, Laboratory of
the Ministry of Agriculture (LMA), Tbilisi, Georgia. Spleen homogenate was used to infect six
6-week-old male specific pathogen-free Large White pigs by oro-nasal (three pigs) or intramus-
cular (three pigs) application. Sera were collected five days after infection for further processing
in this protocol. On the fifth day after infection, the serum of ASFV- infected pigs contained
108 ASFV genome equivalents and was processed as described below. The same protocol can
be applied for isolation of vDNA from cell-culture supernatants containing viral particles.
1. Form a sucrose cushion by adding 2 mL of a 20% sucrose solution in a 13.2 mL ultra-clear
centrifuge tube (Beckman Coulter, see key resources table)
2. Overlay the sucrose with 7 mL of ASFV-infected pig serum by gently pipetting down the side of
the tube
3. Carefully add phosphate buffer saline (PBS) (see key resources table) up to 2–3 mm from the top
of the tube.
4. Centrifuge at 50,000 3 g for 90 min.
Note: Familiarize yourself with the user manual and safety instructions before using the rotor
and operating the ultracentrifuge.
5. Carefully discard the supernatant by pipetting without disturbing the pellet. Usually a discrete
pale-white pellet is visible.
6. Resuspend the pellet in 200 mL of PBS.
7. Extract the virus DNA using the MagAttract HMW DNA Kit (Qiagen) according to manufacturer’s
instructions (see here).
SD-Ura (or-His) plates
Reagents Final concentration Amount
SD Base Agar n/a 46.7 g
-His (or -Ura) n/a 0.77 g
ddH2O n/a Up to 1 L
Adjust the pH to 5.8 and autoclave 121C 15min
Store upside down at 4C up to 2/3 weeks.
LB-chlR12.5 plates
Reagents Final concentration Amount
LB Agar n/a 35 g
Chloramphenicol (50 mg/mL) 12.5 mg/mL 250 mL
ddH2O n/a Up to 1 L
Store upside down at 4C up to 2/3 weeks.
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Transformation-associated recombination (TAR) cloning of ASFV sub-genomic fragments
Timing: 1 day (+ 2 days of incubation after yeast transformation)
This section describes all the necessary steps required for the individual isolation of the different
ASFV sub-genomic fragments in yeast. It encompasses the generation of the different TAR vectors
carrying the appropriate hook sequences up to their individual co-transformation in yeast
spheroplasts along with the previously isolated high-quality ASFV genomic DNA. Each of the five
sub-genomic fragments has to be isolated individually but all the transformations can be performed
in parallel.
8. Insertion of the overlapping regions (hooks) and I-SceI restrictions sites in the pCC1BAC-Ura3
TAR vector
a. pCC1BAC-Ura3 plasmid (10 ng/mL) was used as DNA template in the following PCR reaction.
b. PCR products were separated and visualized on a 0.8% agarose gel containing RedSafe 13,
which is a substitute for ethidium bromide.
c. Optional (but recommended): Add 1 mL ofDpnI restriction enzyme directly to the PCRmixture
without prior treatment and incubate for 1 h at 37C in a temperature-controlled heat block to
digest template DNA. After 1 h, add another 1 mL of DpnI and incubate for an extra hour.
d. DpnI-treated PCR products are purified using the High Pure PCR product purification kit
(Roche) following manufacturer’s recommendations (here).
e. Purified PCR products are quantified individually by measuring the absorbance at 260 nm
using the mCuvette G1.0 of the Biospectrophotomer (Roche) and concentrations are
adjusted to 100 ng/mL when possible.
9. Yeast spheroplasts preparation
a. Start an overnight culture of S. cerevisiae VL6-48N in 10 mL YPDA (pH 6.5) medium at 30C
under agitation (200 rpm).
Reagents Final concentration Amount (for one reaction)
ddH2O n/a 32 mL
53 PrimeSTAR DNA Buffer 13 10 mL
dNTP mixture (2.5 mM each) 200 mM each 4 mL
Forward primer (10 mM) 0.2 mM 1 mL
Reverse primer (10 mM) 0.2 mM 1 mL
PrimeSTAR GXL DNA polymerase 1.25 U 1 mL
DNA template (TAR vector) 10 ng 1 mL
PCR cycling conditions
Steps Temperature (C) Time Cycles
Initial denaturation 98 1 min 1
Denaturation 98 10 s 30
Annealing 52 15 s
Extension 68 10 min
Final extension 68 10 min 1
Hold 10 Forever
PrimeSTAR GXL DNA polymerase was selected as it consistently resulted in specific amplicons. Alternative high-fidelity DNA
polymerases such as the KOD Hot Start DNA polymerase (#71086, Merck) can also be used.
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b. The next morning, measure the OD600nm and use the appropriate volume to start a fresh
100-mL S. cerevisiae VL6-48N culture in YPDA with an initial OD600nm of 0.2.
c. When the OD600nm of this new culture reaches 2, collect yeast cells by centrifugation at
1,7503 g for 3 min, discard the supernatant and resuspend the pellet in 20 mL of 1M sorbitol.
Incubate overnight at 4C.
d. Collect the yeast cells by centrifugation at 1,750 3 g for 3 min at 4C. Resuspend the pellet in
10 mL of SPEM solution (see recipe) in a 50-mL sterile centrifuge tube.
e. Add 20 mL of ß-mercaptoethanol and 20 mL of Zymolyase-100T solution (see recipe) and
incubate at 30C with gentle agitation (80 rpm) until spheroplasts are ready.
CRITICAL: The formation of spheroplasts needs to be assessed by comparing the
OD600nm measurements of a 1/10
th dilution of the spheroplast solution in a 1M sorbitol
solution (intact spheroplasts) versus in a 2% SDS solution (lysed spheroplasts).
Spheroplasts are considered ready when the ratio between the two readings is
comprised between 3 and 4. Ideally, OD600nm of 0.8 and 0.2 should be obtainedwhen cells
are diluted in 1M sorbitol and 2% SDS solutions, respectively.
f. When spheroplasts are ready, add immediately 40 mL of 1M sorbitol and mix gently by
inversion.
g. Collect the yeast cells by centrifugation at 1,200 3 g for 5 min at 4C.
h. Gently resuspend the pellet in 20 mL of 1M sorbitol using a 25-mL serological pipette. Add
another 30 mL of 1M sorbitol and gently invert the tube 2–3 times.
i. Collect spheroplasts by centrifugation at 1,2003 g for 5 min and resuspend the pellet in 2 mL
STC (see recipe). Incubate at room temperature for 10 min.
10. Spheroplast transformation
a. Mix 100 mL of yeast spheroplast with 5 mg of ASFV genomic DNA and 250 ng of the PCR-
amplified pCC1BAC-Ura3 TAR vector containing the appropriate hooks (i.e., sharing
overlaps with the ASFV sub-genomic fragment to clone). Incubate at room temperature
for 10 min.
Note: One transformation is performed per tube, which corresponds to the individual TAR
cloning of one ASFV sub-genomic fragments. In total, seven independent transformations
need to be performed in parallel in order to individually cloned all ASFV sub-genomic
fragments described here.
b. Add 0.5 mL of PEG solution (see recipe). Mix by rotating the tube very gently. Incubate at
room temperature for 20 min.
c. Collect the cells at 2,5003 g for 5 min. Carefully remove the supernatant and resuspend the
pellet in 700 mL SOS solution (see recipe). Incubate for 2 h at 30C.
d. Mix the spheroplasts with 12 mL of melted TOP agar medium (see recipe), previously
equilibrated at 55C in a bead/water bath. Quickly pour the mixture onto Sorbitol-Ura plates
(see recipe) and allow it to solidify for few seconds at room temperature.
e. Incubate at 30C for 2 days.
Note: If no transformants are observed, see the troubleshooting section (problem 1).
PCR-based screening of yeast transformants
Timing: 2 days
This section describes the PCR-mediated identification of yeast transformants carrying the sub-
genomic ASFV fragments of interest. Figure 2 summarizes the different steps involved in this section.
The first step consists in the replication of individual yeast colonies on a new selection plate to ensure
adequate propagation. The first screening relies on the amplification of a short internal region of the
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desired fragment, which is performed on pools of eight yeast colonies to allow a large but rapid
initial pre-screening. The same PCR is then carried out on all individual colonies of previously tested
positive pools to identify individual positive yeast clones. The second and third PCRs target the
junctions between the TAR vector and the ASFV sub-genomic fragments.
11. Pick isolated colonies from the original Sorbitol-Ura plates and patch each of them onto fresh
SD-Ura plates. A total of 32 colonies are usually patched per plate using a 32-square grid
PetriSticker (Sigma-Aldrich). Incubate at 30C for 24 h.
12. Extract yeast (extra)-chromosomal DNA using the glass bead Chelex 100 preparation (GC prep)
method as described elsewhere (Blount et al., 2016).
a. Collect a2-mm2 surface of a yeast patch with the tip of a 20-uL sterile pipette tip and placed
into an 1.5mL-Eppendorf tube containing 100 mL of a 5% Chelex 100 solution (resuspended
in deionized water) and add acid washed glass beads to half total sample volume.
b. Repeat step a) for 7 additional patches (in order to make a pool of 8 colonies)
c. Vortex at 1,400 rpm for 4 min.
d. Incubate for 2 min at 99C and centrifuge at 18,000 3 g for 1 min.
e. Transfer 30–40 mL of the supernatant to a clean tube. Store at 4C for 24–48 h or at20C for
a longer period.
f. Use 1 mL of the supernatant as DNA template in each of the subsequent screening PCRs
13. PCR amplifications of i) the internal genomic DNA region and ii) the two junctions between the
TAR vector and ASFV gDNA fragment are performed. Amplicons obtained from pooled clones
and individual clones are displayed in Figure 3.
Set-up PCR reaction (for one reaction) (GoTaq G2 green master mix)
GoTaq G2 Green Master Mix, 23 12.5mL
upstream primer, 10mM 2 mL
downstream primer, 10mM 2 mL
DNA template (GC prep, step 12) 1 mL
Nuclease-Free Water 7.5 mL
Total 25 mL
Figure 2. Flowchart describing the steps required for the PCR-based screening of yeast transformants
Yeast colonies obtained on Sorb-Ura plates are replicated individually onto a fresh SD-Ura plates. A first GC extraction
is performed on eight patches pooled together into a single tube (‘‘Pool’’ GC preparation). New GC extractions are
then carried out on each of the eight patches from a positive pool (‘‘Individual’’ GC preparations). These steps are
repeated for every TAR-cloned sub-genomic fragment.
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a. PCR reactions are performed using the GoTaq G2 Green Master mix (Promega) according
to manufacturer’s recommendations (see here). The set-up for each reaction is presented in
the following table:
b. PCRs are run following the cycling conditions described below:
Optional: Sanger sequencing of the different PCR products is recommended to confirm the
identity of the ASFV sub-genomic fragment cloned and that the junctions do not contain
any SNPs that would be detrimental for the subsequent steps.
14. Select one or two yeast clones containing the desired fragment for each of the five TAR cloning
experiments for further use. Save these yeast clones at 80C in RotiStore yeast cryo vials
following manufacturer’s conditions (see here).
If no positive yeast transformants are obtained, see troubleshooting section (problem 2).
Figure 3. PCR-based screening and identification of yeast clones carrying an ASFV sub-genomic fragment
(A) Agarose gels showing the amplification products of the internal DNA regions located on ASFV sub-genomic
fragment 3 (left) and sub-genomic fragment 4 (right). PCRs were carried on pools (P) of eight colonies. Pools indicated
in red are considered positives.
(B) Amplification products obtained when the 50 and 30 junctions between the TAR vector and each of the two sub-
genomic fragments were assessed. Plus and minus signs indicate the positive (ASFV gDNA) and negative (water)
controls for each of the PCRs, respectively. GeneRuler 100 bp Plus DNA ladder (Thermo Scientific) was used as
marker (M).
PCR cycling conditions (GoTaq G2 green master mix)
Steps Temperature Time Cycles
Initial denaturation 95 2 min 1
Denaturation 95 15 s 30
Annealing 50 30 s
Extension 72 1 min
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Multicopy plasmid induction in E. coli
Timing: 2 days
This section describes the extraction of the yeast artificial chromosomes (YACs) containing ASFV
sub-genomic fragments from yeast followed by their subsequent transformation into E. coli. The
multicopy induction system present on the pCC1BAC-Ura3 TAR vector is then used to purify larger
amounts of plasmids/YACs required for the final reassembly in yeast.
15. YAC extraction from yeast based on the QIAGEN mini kit
a. Resuspendhalf of the remaining yeast patch from positive clones (from step 16) into 250 mL
of P1 solution (included in the QIAGENmini kit), 25 mL of Zymolyase solution (see recipe) and
2.5 mL of b-mercaptoethanol. Vortex for 10 s and incubate the mixture at 37C for 30 min.
b. Vortex for another 10 s and incubate for 30 min at 37C.
c. Add 250 mL of P2 solution and follow all the next steps according to manufacturer’s instruc-
tions (here) up to the elution step.
d. For the elution step, add 30 mL of elution buffer into the column and let sit for 5 min. Place the
column into a fresh microcentrifuge tube and centrifuge for 1 min at 18,000 3 g at room
temperature.
16. E. coli transformation using Transformax EPI300 electrocompetent cells
a. Chill 1-mm electroporation cuvettes and sterile Eppendorf tubes on ice for 15 min
(one cuvette and one tube per transformation).
b. Add 3 mL of the previously extracted plasmid solution to 35 mL of freshly thawed
Transformax EPI300 electrocompetent E. coli cells in a pre-chilled tube.
c. Transfer the mixture to the pre-chilled 1-mm electroporation cuvette and electroporate
following manufacturer’s instructions. In our case, we used the Gene Pulser Electroporation
system (Bio-Rad) with the following parameters: 2 kV; 25 mFD and 200 Ohms.
d. Add immediately 950 mL of SOC medium and incubate for 1 h at 37C under agitation
(200 rpm).
e. Transfer the mixture to a fresh sterile microcentrifuge tube and centrifuge for 30 s at
18,000 3 g, discard the supernatant.
f. Resuspend the pellet in 200 mL of fresh SOCmedium and plate on selectivemedium (LB-Agar
plates containing 12.5 mg/mL chloramphenicol). Transformants are usually observed after
24 h of incubation at 37C.
Note: An additional 24 hours incubation might ease the picking of the E. coli colonies in some
cases.
17. PCR verification of the E. coli clones.
a. Resuspend one E. coli colony per ASFV sub-genomic fragment in a fresh microcentrifuge
tube containing 10 mL of deionized water.
b. Use 1 mL of the mixture as DNA template for each of the two junction PCRs as previously
described in step 18.
c. Use the remaining 8 mL to start a 12-mL culture in LB-ChlR12.5 for each positive E. coli clone
tested. Incubate for 12–14 h at 37C under agitation (220 rpm).
d. Save one or two E. coli clones at 80C using 750 mL of the overnight cultures mixed with
glycerol (15% final concentration).
18. Multicopy induction and plasmid purification from E. coli clones
a. Use the remaining 10 mL of the overnight culture (from step 22) to start a 100-mL LB-ChlR12.5
culture into a 250-mL Erlenmeyer baffled flask to ensure proper aeration.
b. Add 100 mL of CopyControl induction solution to the culture and incubate for 5 h at 37C
under agitation (220 rpm).
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CRITICAL: Proper aeration of the culture is extremely important to ensure high yields of
plasmid after purification.
c. Centrifuge the culture for 20 min at 4,250 3 g at room temperature. Pellets can be stored
at 20C.
d. Plasmids were extracted using the QIAGEN midiprep plasmid purification kit following
manufacturer’s instructions (here).
e. Quantify DNA concentration using a biospectrophotometer.
Full-length reassembly of ASFV clones
Timing: 1 day (+2 days after yeast transformation)
This section describes the reconstruction of full-length ASFV genomes in yeast. It consists in the co-
transformation of S. cerevisiae with a mixture of precipitated DNA containing all five overlapping
ASFV sub-genomic fragments as well as the two chemically-synthetized fragments 1 and 2. This
section also contains the final screening step of the reconstructed ASFV genomes confirming the
presence of all the junctions between the seven different ASFV sub-genomic fragments.
19. Gel purification of the two synthetic fragments 1 and 2
a. Five micrograms of the pUC57-Fragment1 plasmid were SmaI-digested in five 50-mL total
reaction volume each containing 1 mg of DNA. Digestions were performed following
manufacturer’s instructions (NEB). The same protocol was applied to the digestion of the
pUC57-Fragment2 plasmid.
b. Digested products were loaded on a 1% TAE agarose gel containing RedSafe 13.
Electrophoresis was carried out for 1 h at 50 V (3.85 V/cm).
c. The DNA bands corresponding to the linearized synthetic constructs were excised from the
gel using an X-tracta gel extractor tool (Sigma-Aldrich) after short exposure to blue light
using an LED transilluminator (MaestroGen).
Note: Blue light should be preferred over ultraviolet light to avoid DNA damage during the
purification process
d. The excised gel band was placed in a 1.5-mL microcentrifuge tube and DNA was eluted in
30 mL final volume using the QIAQuick gel extraction kit followingmanufacturer’s instructions
(QIAGEN).
e. Quantify DNA concentrations using a biospectrophotometer. One hundred fmoles of each of
the SmaI-digested Fragment1 and Fragment2 are used for step 26.
20. Linearization of the YACs containing the different ASFV sub-genomic fragments
a. Digest 50 fmoles of each of the ASFV sub-genomic fragments individually by I-SceI following
manufacturer’s instructions (here). If DNA concentration is too low, multiple 50-mL reactions
can be performed in parallel.
b. After 1 h restriction time, add 1 mL of I-SceI to the reaction and incubate for an extra hour.
21. Precipitation of DNA prior yeast transformation
a. All digested ASFV fragments (synthetic and TAR-cloned ones) are pooled together in a
microcentrifuge tube.
b. The total volume (VDNA) of all digested ASFV fragments is calculated. Digested ASFV
fragments is precipitated in a solution containing 1/10th VDNA of isopropanol; 1/10
th
VDNA of 3M NaAc; 1 mL of Glycoblue coprecipitant (ThermoFisher) and 1 mL of tRNA
(Sigma-Aldrich).
c. Centrifuge the mixture at 12,500 3 g for 30 min at 4C and discard the supernatant.
d. Resuspend the pellet in 700 mL of 70% ethanol solution.
e. Centrifuge at 12,500 3 g for 15 min at 4C and discard the supernatant.
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f. Resuspend the pellet in 30 mL of TE buffer (10 mM Tris-HCl pH8; 1 mM EDTA). Store at 4C if
used immediately or at 20C for a longer period.
22. Yeast spheroplast co-transformation with all ASFV sub-genomic fragments and final pCC1BAC-
His3 TAR vector
a. Yeast spheroplasts were prepared as previously described (step 14).
b. Mix yeast spheroplast with 250 ng of PCR-amplified pCC1BAC-His3 and the 30 mL of all seven
precipitated ASFV fragments.
c. The following steps were performed as previously described in step 15 with the exception
that yeast cells were plated on Sorbitol-His plates instead of Sorbitol-Ura. Transformants
can be observed after 24 h and colonies are big enough to be picked after 48 h.
23. Screening of yeast transformants using multiplex PCR
a. Patch yeast colonies onto a fresh SD-His plate.
b. Extract yeast DNA using the GC-prep method as previously described (step 17)
c. Use 1 mL as DNA template and set up two independent multiplex PCR reactions for individual
colonies using the QiagenMultiplex PCR kit (Qiagen) following manufacturer’s instructions
(here). Expected profiles for ASFV full-length clones are presented in Figure 4. All primers
included in each multiplex PCR can be found in the primer table here. The set-up for each
reaction is presented in the following table:
d. Cycling conditions for the two PCRs are described in the table below:
24. Select one or two yeast positive transformants for further use. Biobank these yeast clones at
80C in RotiStore yeast cryo vials following manufacturer’s conditions (see here).
If no positive yeast transformants are obtained, see troubleshooting section (problem 5).
25. Large-scale preparation of full-length ASFV genomic DNA
a. YAC extraction from yeast
i. Start a 500-mL culture of S. cerevisiae containing full-length ASFV construct in SD-His at
30C under agitation in a 2 L baffled Erlenmeyer flask.
ii. When OD600nm reaches 2, centrifuge the culture at 4,250 3 g for 20 min at 4C.
iii. Resuspend the pellet in a solution containing 20 mL of P1 solution (included in the
QIAGEN Large-construct kit), 2 mL of Zymolyase solution (see recipe) and 200 mL of
b-mercaptoethanol. Vortex for 30 s and incubate the mixture at 37C for 1 h.
iv. Vortex for another 30 s and incubate for another 1 h min at 37C.
Set-up PCR reaction (for one reaction) (multiplex PCR kit Qiagen)
23 QIAGEN Multiplex PCR Master Mix 12.5 mL
103 primer mix, 2 mM each primer 2.5 mL
RNase-free water 9 mL
DNA template (GC prep, step 23b) 1 mL
Total 25 mL
PCR cycling conditions
Steps Temperature Time Cycles
Initial denaturation 95 15 min 1
Denaturation 95 1 min 35
Annealing 50 2.5 min
Extension 72 1.5 min
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v. DNA extraction is performed using the Qiagen Large-construct kit following manufac-
turer’s instructions (here)
b. Plasmid extraction from E. coli
i. Repeat steps 20 and 21 with an S. cerevisiae clone carrying a full-length ASFV construct.
ii. Proceed to DNA extraction using the Qiagen Large-construct kit starting with a 300-mL
E. coli culture following manufacturer’s instructions (here).
Note: Alternatively, agarose plugs containing intact ASFV chromosome-sized DNA can be
prepared followingmanufacturer’s instructions (here). Such plugs can be prepared from either
E. coli or yeast cultures using the CHEF Bacterial Genomic DNA plug kit (Bio-Rad, 1703592) or
CHEF Yeast Genomic DNA plug kit (Bio-Rad, 1703593), respectively.
Genetic engineering of ASFV clones
Timing: 3 days
This section describes the necessary steps for the engineering of the ASFV genome using the
previously isolated sub-genomic fragments. Here, we substituted one non-essential gene in
Fragment 4 (namely the C962R gene; Figure 5, in dark gray) (Ramirez-Medina et al., 2020) and
replaced it by chemically-synthetized DNA cassettes carrying reporter genes as a proof of concept.
26. Design of the chemically-synthetized DNA cassettes carrying the reporter genes
a. SmaI restrictions sites (indicated with asterisks in Figure 5): Two SmaI restrictions sites were
added at the 50 and 30 ends of the DNA cassettes to ensure linearization and purification from
the pUC57 backbone plasmid.
b. 50-overlap (Figure 5, in light gray): a region of 250 bp, overlapping the ASFV genome
upstream of the C962R coding sequence included in the ASFV sub-genomic fragment 4,
was added to ensure legitimate recombination in yeast.
Figure 4. Identification of positive full-length clones using multiplex PCRs screening
Two independent multiplex PCRs were performed on full-length assembled ASFV constructs with two sets of primers
in order to ensure the presence of all junctions between the different ASFV sub-genomic fragments. Amplification
profiles expected for the multiplex Set1 (top) and multiplex Set2 (bottom) can be observed for positive clones (in red).
Expected sizes of the PCR products are indicated on the left side of the gels. GeneRuler 100 bp Plus DNA ladder
(Thermo Scientific) was used as marker (M).
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c. Promoter region (Figure 5, in yellow): the promoter region of the DNA polymerase (G1211R)
of the ASFV Armenia isolate was used as previously reported (Portugal et al., 2017).
d. Reporter sequences: the respective 720-bp and 600-bp nucleotide sequence of the
enhanced GFP (eGFP) (Figure 5, in green) and secreted Luciferase (secNLuc) (Figure5, in
pink) obtained from Promega were added in frame with the promoter region.
e. Terminator sequence (Figure 5, in red): the 281-bp terminator sequence of the thymidine
kinase (TK, L60) was added after the reporter sequences in both constructs (Portugal et al.,
2017).
f. 30-overlap (Figure 5, in orange): a 387-bp region consisting of the last 65 bp of the 30UTR of
the C962R open reading frame (Cackett et al., 2020). The rest of the sequence, overlapping
with the ASFV sub-genomic fragment 5, was added to ensure legitimate recombination in
yeast.
27. Isolation of the ASFV sub-genomic fragment 4 deleted for the C962R gene
a. Generation of pCC1BAC-Ura3 with appropriate hooks. A PCR amplification of the pCC1BAC-
Ura3 TAR vector was carried out with primers ASFTARhook4-R/F2 as reported in step 8.
b. Yeast clones carrying the ASFV sub-genomic fragment 4 deleted for C962R were obtained
using TAR cloning as reported in steps 9 and 10.
c. Repeat steps 11 to 18 in order to obtain purified YACs containing the ASFV sub-genomic
fragment 4 deleted for C962R.
28. Full-length reassembly of genetically engineered ASFV genomes carrying eGFP or secNLuc
reporter genes
a. Repeat steps 24 to 30 including one of the two chemically-synthetized DNA cassettes,
namely pUC57-P_Pol-secNluc _C962R-int or pUC57-P_Pol-eGFP_C962R-int, previously gel
purified along with all the required ASFV sub-genomic fragments.
Figure 5. Design for the replacement of the ASFV C962R gene with synthetic DNA cassettes carrying the eGFP or
secNLuc reporter genes
The ASFV sub-genomic fragment 4 excluding the C962R gene (Fragment 4DC962R) was first isolated using TAR
cloning. Two DNA cassettes, namely the P_Pol-eGFP_C962R-int or P_Pol-secNLuc_C962R-int, were chemically
synthesized and cloned in the pUC57 plasmid. They carry either the eGFP and secreted Luciferease reporter genes
and contain overlaps with their neighboring fragments during genome reassembly, namely Fragment 4DC962R and
Fragment 5. Asterisks indicate the presence of SmaI restriction sites used for linearization. All genetic features
included in the synthetic DNA cassettes are detailed in step 31.
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EXPECTED OUTCOMES
The main outcome of this protocol is to provide a fast and flexible genetic engineering platform for
the modification of genomes derived from large DNA viruses, such as the ASFV, to the scientific
community. All full-length constructs (wild-type full-length ASFV construct and its respective
eGFP and secNLuc versions), as well as all the individual ASFV sub-genomic fragments described
in the protocol will be made available to the scientific community upon request.
LIMITATIONS
One current limitation of the system is the need to clone all sub-genomic fragments in E. coli prior to
the final reassembly in yeast. This is due to the difficulties encountered when large YACs have to be
purified directly from S. cerevisiae. Indeed, YACs such as the ones described here are maintained as
single copy plasmid in yeast. Along with the purification issues due to yeast genomic contamination,
it is technically challenging to produce large quantities of pure YACs from yeast cultures.
Propagation of the constructs in E. coli can be associated with SNPs introductions or stability issues.
Efforts are ongoing to circumvent these difficulties so that a ‘‘yeast-only’’ system can be achieved.
TROUBLESHOOTING
Problem 1
No colonies are obtained after yeast spheroplast transformation (step 15)
Potential solutions
Make sure that the ratio observed in step 9.e during spheroplast formation is correct. A significantly
different ratio will affect the competency of the yeast preparation. If needed, a second culture can be
started and used as backup in case the first culture fails to provide the appropriate ratio.
Check that the proper auxotrophic marker was used to prepare the agar plates.
Ensure that the PEG solution has been freshly prepared and that the pH of the all solutions is
adequate.
The amount of DNA to use for the yeast transformation should not exceed 10%–20% of the total re-
action volume. A large DNA volume will negatively impact the transformation efficiency.
Problem 2
No positive yeast clones obtained after the PCR-based screening (step 18)
Potential solutions
Always confirm that the TAR vector has been specifically amplified. Always include a negative control
in each transformation experiment consisting of the PCR-amplified TAR vector only. If a high number
of colonies is present on the negative control plate, consider doing another round ofDpnI treatment
or gel-purify your TAR vector before use.
Ensure that the primers used to PCR amplify the TAR vector have been designed correctly. As these
primers are typically 80-nt long, it is generally recommended to add an extra PAGE purification
step after synthesis.
The sequences used for the overlapping regions should be unique and should not consist of highly
repetitive regions that can trigger illegitimate recombination during TAR cloning.
Check the quality of the purified viral DNA. This is of great importance, especially when large sub-
genomic DNA fragments are to be TAR-cloned.
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Ensure that the GC extractions as well as the designed primers do not alter the amplification of the
targeted internal regions by running appropriate PCR controls including a positive one using ASFV
genomic DNA as template.
Problem 3
Low concentration of DNA after induction in E. coli (step 23)
Potential solutions
Make sure that the aeration of the E. coli culture is optimal. To do so, make sure to use baffled
Erlenmeyer flasks able to contain at least 5 times the volume of culture actually used.
Problem 4
Incorrect DNA profiles after I-SceI digestion (step 25)
Potential solutions
Check for the presence and correct sequence of each the I-SceI restriction sites by Sanger
sequencing after PCR amplification. If problems are observed, use a different E. coli clone.
Determine the presence of possible genomic DNA contamination in your samples by loading each of
them on a 0.8% agarose gel (as shown in Figure 6). Genomic DNA contamination might artificially
decrease the concentration of plasmid DNA in your samples. If so, start a new plasmid DNA prep-
aration and reduce the initial volume of the culture to 50 mL.
Mechanical shearing might be observed on a 0.8% agarose gel as a DNA smear. Make sure to slowly
and carefully mix your plasmid DNA preparations by pipetting at little as possible or use wide-bore
tips if necessary.
Problem 5
No positive full-length clones after screening using the multiplex PCRs (step 28)
Potential solutions
Make sure that all the PCRs included in the multiplex PCR reactions are working when performed
individually using the genomic DNA as DNA template.
Figure 6. Restrictions profiles of ASFV subgenomic fragments extracted from yeast or E. coli
Agarose gel showing plasmid DNA extracted from S. cerevisiae (YAC) or E. coli (BAC) undigested (-) or digested with
I-SceI (+) for two different ASFV sub-genomic fragments. Red asterisks indicated the presence of genomic DNA in the
plasmid extractions, which is particularly present and problematic when plasmids are extracted from yeast cultures.
The expected digestion pattern is shown by the two red arrows corresponding to the linearized ASFV sub-genomic
fragments (top) and TAR vector (bottom), respectively, and only obtained with E. coli derived plasmid DNA. The
Lambda DNA/HindIII ladder (ThermoFischer) (Thermo Scientific) was used as marker (M).
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Make sure that each sub-genomic fragment overlap its two neighboring fragments by at least 50 bp.
Make sure that all sub-genomic fragments were included in the pool of DNA transformed in yeast.
RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to Dr. Fabien
Labroussaa. Email: fabien.labroussaa@vetsuisse.unibe.ch
Materials availability
All plasmids and resources generated during this study will be made available upon request.
Recipients will be asked for proofs concerning their capacities to work with BSL-2 and BSL-3 agents
before any shipment of material.
Data and code availability
The genomic sequence of the abovementioned ASFV isolate was determined using Illumina
sequencing performed at the Next-Generation Sequencing platform (University of Bern). The
sequence is identical to the isolate Georgia 2007/1 (GenBank: FR682468.2) previously published
(Chapman et al., 2011).
This protocol does not report original code.
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